Plan B or bust for Glycomimetics
The failure of its lead sickle cell project forces Glycomimetics to pivot to a leukaemia asset, but the company’s approach has taken a huge blow.
EHA 2019 – Global Blood faces sickle cell questions
More data with voxelotor shouldn’t hurt the project’s bid for accelerated approval, but there are still doubts about its effect on a harder patient outcome.
Emmaus tries to move forwards by reversing
The company insists that its sickle cell disease therapy Endari still has a future, despite questionable efficacy and the approach of new treatments.
Upcoming events – Pfizer and Glycomimetics await sickle cell data and Biocryst tries again
Rivipansel needs to help sickle cell patients leave hospital sooner and BCX7353 faces established hereditary angioedema agents.
Global Blood aims for sickle cell dominance
Global Blood punching above its weight in sickle cell as 2022 sales forecasts for voxelotor hit $529m in 2022.
